Post-operative thoracic irradiation with or without levamisole in non-small cell lung cancer: results of a radiation therapy oncology group study
| Autor: | Marie Zinninger, Linda Martin Durbin, Arnold Herskovic, Carlos A. Perez, Madeline Bauer, R.L. Scotte Doggett, Raymond Yesner, H. Gunter Seydel |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Nausea medicine.medical_treatment Neutropenia Placebo Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Carcinoma Small Cell Lung cancer Aged Pneumonitis Clinical Trials as Topic Chemotherapy Radiation business.industry Radiotherapy Dosage Middle Aged Levamisole medicine.disease Combined Modality Therapy Surgery Radiation therapy Lymphatic Metastasis medicine.symptom business Follow-Up Studies medicine.drug |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 14:37-42 |
| ISSN: | 0360-3016 |
| Popis: | The Radiation Therapy Oncology Group conducted a Phase III single blind trial to evaluate the addition of Levamisole to post-operative thoracic irradiation (200 cGy five times weekly to a total of 5000 cGy plus 1000 cGy boost) in patients with resected RTOG Stage II-III non-small cell lung cancer with positive nodes. Between February 1980 and February 1983, 74 patients from 18 RTOG institutions were randomized; accrual to this study was prematurely terminated due to poor accrual and the inferior survival observed in the levamisole-treated patients on another RTOG trial. Sixty-four patients were evaluable; 32 assigned to levamisole and 32 were assigned to placebo. Over 95% of the patients have been followed for a minimum of 4 years or to death. Two patients on placebo and 5 on levamisole experienced Grade 3 pneumonitis or esophagitis; 1 patient on placebo and 2 on levamisole experienced Grade 3 pulmonary fibrosis. Three patients on levamisole experienced other Grade 3 or 4 toxicity: 1 case of intractable nausea and vomiting and 2 with Grade 4 neutropenia (less than 500 per mm3). There were no fatal complications. Median disease-free survival was 13 months in the placebo group and 9 months for the levamisole group. Median time to distant metastases was 18 and 12 months, and median survival was 20 and 13 months, respectively. We concluded that this study failed to demonstrate an advantage for levamisole. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|